Michigan Nanotechnology Institute for Medicine and Biological Sciences, Michigan Medicine, University of Michigan, Ann Arbor, MI, United States.
BlueWillow Biologic, Ann Arbor, MI, United States.
Vaccine. 2020 Apr 23;38(19):3537-3544. doi: 10.1016/j.vaccine.2020.03.026. Epub 2020 Mar 31.
Vaccination is the most effective approach to prevent infection with highly pathogenic avian influenza (HPAI). Adjuvants are often used to induce effective immune responses and overcome the immunological weakness of recombinant HPAI antigens. Given the logistical challenges of immunization to HPAI during pandemic situations, vaccines administered via the intramuscular (I.M.) route would be of value.
A new formulation of nanoemulsion adjuvant (NE02) suitable for I.M. vaccination was developed. This NE02 was evaluated alone and in combination with CpG to develop H5 immune responses in mouse and ferret models. Measures of recombinant H5 (rH5) specific immunity evaluated included serum IgG and IgG subclasses, bronchoalveolar lavage fluid IgA, and cytokines. The activation of NF-kB was also analyzed. The efficacy of the vaccine was assessed by performing hemagglutination inhibition (HAI), virus neutralization (VN) assays, and viral challenges in ferrets.
I.M. vaccination with rH5-NE02 significantly increased rH5-specific IgG and protected ferrets in the viral challenge model providing complete protection and sterile immunity in all animals tested. Combining NE02 and CpG produced accelerated antibody responses and this was accompanied by an elevation of IFN-γ and IL-17 responses and the downregulation of IL-5. The combination also caused a synergistic effect on NF-kB activation. In immunized ferrets after viral challenge, the rH5-NE02 + CpG vaccine via I.M. achieved at least 75% and 88% seroconversion of HAI and VN antibody responses, respectively, and improved body temperature stabilization and weight loss over NE02 alone.
The I.M. injection of NE02 adjuvanted rH5 elicits strong and broad immune responses against H5 antigens and effectively protects animals from lethal H5 challenge. Combining this adjuvant with CpG enhanced immune responses and provided improvements in outcomes to viral challenge in ferrets. The results suggest that combinations of adjuvants may be useful to enhance H5 immune responses and improve protection against influenza infection.
接种疫苗是预防高致病性禽流感(HPAI)感染的最有效方法。佐剂常用于诱导有效的免疫反应,并克服重组 HPAI 抗原的免疫弱点。鉴于大流行期间对 HPAI 进行免疫接种的后勤挑战,通过肌内(I.M.)途径接种的疫苗将具有价值。
开发了一种适合 I.M. 接种的新型纳米乳佐剂(NE02)配方。单独评估了这种 NE02,并与 CpG 联合用于在小鼠和雪貂模型中开发 H5 免疫反应。评估的重组 H5(rH5)特异性免疫的措施包括血清 IgG 和 IgG 亚类、支气管肺泡灌洗液 IgA 和细胞因子。还分析了 NF-kB 的激活。通过在雪貂中进行血凝抑制(HAI)、病毒中和(VN)测定和病毒挑战来评估疫苗的功效。
rH5-NE02 的 I.M. 接种显著增加了 rH5 特异性 IgG,并在病毒挑战模型中保护了雪貂,为所有测试动物提供了完全保护和无菌免疫。NE02 与 CpG 联合使用可产生加速的抗体反应,这伴随着 IFN-γ和 IL-17 反应的升高和 IL-5 的下调。这种组合还对 NF-kB 的激活产生协同作用。在病毒挑战后的免疫雪貂中,rH5-NE02+CpG 通过 I.M. 接种分别实现了 HAI 和 VN 抗体反应的至少 75%和 88%的血清转化率,并改善了体温稳定和体重减轻,优于单独的 NE02。
I.M. 注射 rH5 佐剂 NE02 可引发针对 H5 抗原的强烈和广泛的免疫反应,并有效保护动物免受致命 H5 挑战。将这种佐剂与 CpG 联合使用可增强免疫反应,并改善雪貂对病毒挑战的结果。结果表明,佐剂的组合可能有助于增强 H5 免疫反应并提高对流感感染的保护。